Werewolf Therapeutics (HOWL) Accounts Payables (2020 - 2026)
Werewolf Therapeutics (HOWL) posted quarterly Accounts Payables of $1.9 million for Q2 2026, down 30.1% year-over-year from $2.8 million in Q2 2025, and down 45.67% on a QoQ basis from $3.6 million in Q1 2026.
Werewolf Therapeutics (HOWL) Accounts Payables (2020 - 2026) Analysis & Trends
Werewolf Therapeutics has reported Accounts Payables for 7 years, with the latest figure at $1.9 million in Q2 2026.
- Accounts Payables for Q2 2026 came in at $1.9 million, down 30.1% year-over-year; the trailing twelve-month figure through Jun 2026 was $1.9 million (down 30.1% YoY), and the FY2025 annual result was $754000.0, down 75.16% from the prior year.
- Accounts Payables slipped to $1.9 million in Q2 2026, from $3.6 million in the prior quarter.
- Over five years, Accounts Payables peaked at $3.6 million in Q1 2026 and troughed at $754000.0 in Q4 2025.
- A 5-year average of $1.7 million and a median of $1.4 million in 2022 frame the typical range for Accounts Payables.
- The widest annual swing landed in 2025, when Accounts Payables plunged 75.16%; it then soared 261.97% in 2026.
- A 5-year view of Accounts Payables shows it stood at $1.2 million in 2022, then advanced by 9.42% to $1.3 million in 2023, then jumped by 127.17% to $3.0 million in 2024, then plunged by 75.16% to $754000.0 in 2025, then jumped by 157.16% to $1.9 million in 2026.
- Per Business Quant data, the three most recent Accounts Payables figures were $1.9 million in Q2 2026, $3.6 million in Q1 2026, and $754000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Werewolf Therapeutics | 43.94 Mn | 43.94 Mn | - | 1.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.94 Mn |
| Mar 31, 2026 | 3.57 Mn |
| Dec 31, 2025 | 754,000.00 |
| Sep 30, 2025 | 1.08 Mn |
| Jun 30, 2025 | 2.77 Mn |
| Mar 31, 2025 | 986,000.00 |
| Dec 31, 2024 | 3.04 Mn |
| Sep 30, 2024 | 1.24 Mn |
| Jun 30, 2024 | 1.47 Mn |
| Mar 31, 2024 | 1.59 Mn |
| Dec 31, 2023 | 1.34 Mn |
| Sep 30, 2023 | 1.39 Mn |
| Jun 30, 2023 | 1.49 Mn |
| Mar 31, 2023 | 2.11 Mn |
| Dec 31, 2022 | 1.22 Mn |
| Sep 30, 2022 | 1.39 Mn |
| Jun 30, 2022 | 2.59 Mn |
| Mar 31, 2022 | 1.38 Mn |
| Dec 31, 2021 | 2.04 Mn |
| Sep 30, 2021 | 1.46 Mn |